Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experience.

MLA

Jeong, Wirawan, et al. “Safety, Clinical Effectiveness and Trough Plasma Concentrations of Intravenous Posaconazole in Patients with Haematological Malignancies and/or Undergoing Allogeneic Haematopoietic Stem Cell Transplantation: Off-Trial Experience.” The Journal of Antimicrobial Chemotherapy, vol. 71, no. 12, Dec. 2016, pp. 3540–47. EBSCOhost, https://doi.org/10.1093/jac/dkw322.

APA

Jeong, W., Haywood, P., Shanmuganathan, N., Lindsay, J., Urbancic, K., Ananda-Rajah, M. R., Chen, S. C. A., Bajel, A., Ritchie, D., Grigg, A., Seymour, J. F., Peleg, A. Y., Kong, D. C. M., & Slavin, M. A. (2016). Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experience. The Journal of Antimicrobial Chemotherapy, 71(12), 3540–3547. https://doi.org/10.1093/jac/dkw322

Chicago

Jeong, Wirawan, Peter Haywood, Naranie Shanmuganathan, Julian Lindsay, Karen Urbancic, Michelle R Ananda-Rajah, Sharon C A Chen, et al. 2016. “Safety, Clinical Effectiveness and Trough Plasma Concentrations of Intravenous Posaconazole in Patients with Haematological Malignancies and/or Undergoing Allogeneic Haematopoietic Stem Cell Transplantation: Off-Trial Experience.” The Journal of Antimicrobial Chemotherapy 71 (12): 3540–47. doi:10.1093/jac/dkw322.